Video

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, discusses the results of the longest follow-up survival study of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, and investigator at the Ludwig Center at Harvard, discusses the results of a 5-year follow-up analysis of survival outcomes of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

The phase I study of nivolumab, which was conducted in 2008, examined the survival outcomes of 107 heavily pretreated patients treated with nivolumab. With the long-term follow-up, Hodi noted there were no new safety signals and no treatment-related deaths. Moreover, 34% of patients remained alive at the 5-year follow-up.

This study's results show that anti—PD-1 therapy can give long-term benefits to patients with advanced melanoma. Hodi is hopeful that this benefit will translate to patients treated with nivolumab with other cancers, as well.

<<<

View more from the 2016 AACR Annual Meeting

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Toni K. Choueiri, MD
Neil J. Shah, MBBS
Mary Philip, MD, PhD
Rom S. Leidner, MD
Sarwish Rafiq, PhD
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center